Anya Biopharm Statistics

Total Valuation

Anya Biopharm has a market cap or net worth of TWD 1.51 billion. The enterprise value is 1.15 billion.

Market Cap	1.51B
Enterprise Value	1.15B

Important Dates

The next estimated earnings date is Monday, May 4, 2026.

Earnings Date	May 4, 2026
Ex-Dividend Date	n/a

Share Statistics

Anya Biopharm has 49.10 million shares outstanding. The number of shares has increased by 48.38% in one year.

Current Share Class	49.10M
Shares Outstanding	49.10M
Shares Change (YoY)	+48.38%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	21.45%
Owned by Institutions (%)	2.96%
Float	27.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	92.95
PB Ratio	3.75
P/TBV Ratio	3.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.89
EV / Sales	70.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.17

Financial Position

The company has a current ratio of 47.95, with a Debt / Equity ratio of 0.01.

Current Ratio	47.95
Quick Ratio	47.27
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.04
Interest Coverage	-112.83

Financial Efficiency

Return on equity (ROE) is -14.72% and return on invested capital (ROIC) is -8.32%.

Return on Equity (ROE)	-14.72%
Return on Assets (ROA)	-8.15%
Return on Invested Capital (ROIC)	-8.32%
Return on Capital Employed (ROCE)	-14.38%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

In the past 12 months, Anya Biopharm has paid 685,000 in taxes.

Income Tax	685,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.76% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+6.76%
50-Day Moving Average	32.72
200-Day Moving Average	42.30
Relative Strength Index (RSI)	50.82
Average Volume (20 Days)	77,596

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Anya Biopharm had revenue of TWD 16.27 million and -64.02 million in losses. Loss per share was -1.30.

Revenue	16.27M
Gross Profit	16.13M
Operating Income	-58.33M
Pretax Income	-63.32M
Net Income	-64.02M
EBITDA	-56.83M
EBIT	-58.33M
Loss Per Share	-1.30

Full Income Statement

Balance Sheet

The company has 370.22 million in cash and 2.96 million in debt, giving a net cash position of 367.26 million or 7.48 per share.

Cash & Cash Equivalents	370.22M
Total Debt	2.96M
Net Cash	367.26M
Net Cash Per Share	7.48
Equity (Book Value)	402.85M
Book Value Per Share	8.20
Working Capital	384.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -69.93 million and capital expenditures -872,000, giving a free cash flow of -70.81 million.

Operating Cash Flow	-69.93M
Capital Expenditures	-872,000
Depreciation & Amortization	1.51M
Net Borrowing	-160,000
Free Cash Flow	-70.81M
FCF Per Share	-1.44

Full Cash Flow Statement

Margins

Gross Margin	99.14%
Operating Margin	-358.52%
Pretax Margin	-389.18%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Anya Biopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-48.38%
Shareholder Yield	-48.38%
Earnings Yield	-4.23%
FCF Yield	-4.68%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Anya Biopharm has an Altman Z-Score of 108.47 and a Piotroski F-Score of 1.

Altman Z-Score	108.47
Piotroski F-Score	1